Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FGES9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,318
Award facts
- Contract value 100% obligated
- $19,318.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $19,318.30 delivery order to DMS Pharmaceutical Group Inc. for Nucala 100 mg/mL auto-injector on January 27, 2026, with an ultimate completion date of January 28, 2026. This delivery order was issued without a set-aside designation under a firm fixed-price arrangement and will be performed at the contractor's location in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was selected to supply this immunosuppressant biologic therapy used in the treatment of asthma and eosinophilic conditions.
This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy established to provide comprehensive pharmaceutical support to Department of Defense military healthcare facilities worldwide. The underlying PPV-G GEN V contract, valued at $499.999 billion with a completion date of December 31, 2036, authorizes the DLA to issue delivery orders for branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables. DMS Pharmaceutical Group's substantial federal contracting activity and demonstrated capability across diverse therapeutic categories position it as a critical regional pharmaceutical supplier supporting recurring medical supply needs across the global military healthcare system.
Quick answers
Who was awarded contract SPE2DR26FGES9?
SPE2DR26FGES9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FGES9 worth?
The government has obligated $19,318 on SPE2DR26FGES9.
Is contract SPE2DR26FGES9 an order under another contract?
Yes. SPE2DR26FGES9 is a delivery order under SPE2DR25D9312, an indefinite delivery contract.
Was contract SPE2DR26FGES9 competed?
The extent of competition for SPE2DR26FGES9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award